Stockreport

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) [Yahoo! Finance]

GlycoMimetics, Inc.  (GLYC) 
Last glycomimetics, inc. earnings: 5/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.glycomimetics.com/investor-relations
PDF Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the upro [Read more]